|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US6416998B1
(en)
|
1992-09-02 |
2002-07-09 |
Baylor College Of Medicine |
Plasmid encoding a modified steroid hormone
|
|
US5846945A
(en)
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
AU7326594A
(en)
|
1993-07-09 |
1995-02-06 |
Synergen, Inc. |
Recombinant ctla4 polypeptides and methods for making the same
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
JP3926842B2
(ja)
|
1995-03-08 |
2007-06-06 |
ザ・スクリプス・リサーチ・インステイチユート |
抗原提示系およびｔ−細胞の活性化方法
|
|
US5763270A
(en)
|
1995-06-07 |
1998-06-09 |
Genemedicine, Inc. |
Plasmid for delivery of nucleic acids to cells and methods of use
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
ATE347588T1
(de)
|
1996-05-23 |
2006-12-15 |
Scripps Research Inst |
Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
PT1053325E
(pt)
|
1998-02-05 |
2006-05-31 |
Glaxosmithkline Biolog Sa |
Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
|
|
JP2002524081A
(ja)
|
1998-09-04 |
2002-08-06 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
前立腺−特異的膜抗原に特異的な融合受容体およびその使用
|
|
WO2000023573A2
(en)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
|
|
DK1141028T3
(da)
|
1998-12-23 |
2010-05-25 |
Pfizer |
Humane monoklonale antistoffer til CTLA-4
|
|
US6790662B1
(en)
|
1999-03-12 |
2004-09-14 |
Ortho-Mcneil Pharmaceutical, Inc. |
Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
|
|
DE60014076T2
(de)
|
1999-04-19 |
2005-10-13 |
Glaxosmithkline Biologicals S.A. |
Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
US20020131960A1
(en)
|
2000-06-02 |
2002-09-19 |
Michel Sadelain |
Artificial antigen presenting cells and methods of use thereof
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
US20040071671A1
(en)
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US20030211603A1
(en)
|
2001-08-14 |
2003-11-13 |
Earp David J. |
Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
WO2004028563A1
(en)
|
2002-09-27 |
2004-04-08 |
Genexine Inc. |
A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
EP2216342B1
(en)
|
2003-07-31 |
2015-04-22 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
US7682828B2
(en)
|
2003-11-26 |
2010-03-23 |
Whitehead Institute For Biomedical Research |
Methods for reprogramming somatic cells
|
|
AU2005282414C1
(en)
|
2004-09-08 |
2011-04-07 |
Wisconsin Alumni Research Foundation |
Culturing human embryonic stem cells
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
EP3147296A1
(en)
|
2005-11-14 |
2017-03-29 |
Merial, Inc. |
Gene therapy for renal failure
|
|
US8129187B2
(en)
|
2005-12-13 |
2012-03-06 |
Kyoto University |
Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
|
|
US8278104B2
(en)
|
2005-12-13 |
2012-10-02 |
Kyoto University |
Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
|
|
BRPI0619794B8
(pt)
|
2005-12-13 |
2022-06-14 |
Univ Kyoto |
Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
|
|
ES2579762T3
(es)
|
2006-03-01 |
2016-08-16 |
Janssen Pharmaceutica N.V. |
Tratamiento del cáncer combinando agente linfo - reductor con CLTs y citoquinas
|
|
CA2665568C
(en)
|
2006-10-04 |
2018-01-09 |
Janssen Pharmaceutica, N.V. |
Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
|
|
DK3399025T3
(da)
|
2007-03-23 |
2025-06-16 |
Wisconsin Alumni Res Found |
Omprogrammering af somatiske celler
|
|
CA2682527C
(en)
|
2007-03-30 |
2017-07-11 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
US9683232B2
(en)
|
2007-12-10 |
2017-06-20 |
Kyoto University |
Efficient method for nuclear reprogramming
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
EP3279314A1
(en)
|
2008-06-04 |
2018-02-07 |
Cellular Dynamics International, Inc. |
Methods for the production of ips cells using non-viral approach
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
JP2012500005A
(ja)
|
2008-08-12 |
2012-01-05 |
セルラー ダイナミクス インターナショナル， インコーポレイテッド |
ｉＰＳ細胞を生成するための方法
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
CA2741090C
(en)
|
2008-10-24 |
2018-10-16 |
Wisconsin Alumni Research Foundation |
Pluripotent stem cells obtained by non-viral reprogramming
|
|
DK2438160T3
(en)
|
2009-06-05 |
2016-01-11 |
Cellular Dynamics Int Inc |
Reprogramming of T cells and hematopoietic cells
|
|
KR101774206B1
(ko)
|
2009-08-07 |
2017-09-04 |
고쿠리츠 다이가쿠 호진 교토 다이가쿠 |
유도된 다능성 줄기 세포의 효율적인 확립 방법
|
|
US8889394B2
(en)
|
2009-09-07 |
2014-11-18 |
Empire Technology Development Llc |
Multiple domain proteins
|
|
ES2539487T3
(es)
|
2009-11-04 |
2015-07-01 |
Cellular Dynamics International, Inc. |
Reprogramación episómica con compuestos químicos
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
US9005967B2
(en)
|
2010-01-22 |
2015-04-14 |
Kyoto University |
Myc variants improve induced pluripotent stem cell generation efficiency
|
|
PL3053932T3
(pl)
|
2010-02-19 |
2021-03-08 |
Xencor, Inc. |
Nowe immunoadhezyny CTLA4-IG
|
|
JP6208580B2
(ja)
|
2010-05-17 |
2017-10-04 |
サンガモ セラピューティクス， インコーポレイテッド |
新規のｄｎａ結合タンパク質及びその使用
|
|
JP5984217B2
(ja)
|
2010-06-15 |
2016-09-06 |
セルラー ダイナミクス インターナショナル， インコーポレイテッド |
少量の末梢血からの人工多能性幹細胞の作製
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CN110200997A
(zh)
|
2011-03-23 |
2019-09-06 |
弗雷德哈钦森癌症研究中心 |
用于细胞免疫治疗的方法和组合物
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
KR102134932B1
(ko)
|
2011-11-11 |
2020-07-17 |
프레드 헛친슨 켄서 리서치 센터 |
암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
SG10201609210SA
(en)
|
2012-05-03 |
2016-12-29 |
Hutchinson Fred Cancer Res |
Enhanced affinity t cell receptors and methods for making the same
|
|
KR102437522B1
(ko)
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
CA2881981A1
(en)
|
2012-08-20 |
2014-02-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
AU2013327136A1
(en)
|
2012-10-02 |
2015-04-16 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
EP2906684B8
(en)
|
2012-10-10 |
2020-09-02 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
MX2015015638A
(es)
|
2013-05-13 |
2016-10-28 |
Cellectis |
Metodos para diseñar celulas t altamente activas para inmunoterapia.
|
|
CA2917858A1
(en)
|
2013-08-02 |
2015-02-05 |
Aduro Biotech Holdings, Europe B.V. |
Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
EP4043556B1
(en)
|
2015-06-30 |
2024-02-07 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
|
ES2970269T3
(es)
*
|
2015-07-29 |
2024-05-27 |
Onk Therapeutics Ltd |
Linfocitos citolíticos naturales modificados y líneas de linfocitos citolíticos naturales que tienen citotoxicidad aumentada
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
ES2952064T3
(es)
*
|
2015-12-16 |
2023-10-26 |
Walter & Eliza Hall Inst Medical Res |
Inhibición de la proteína SH2 inducida por citocinas en células NK
|
|
JP7177047B2
(ja)
|
2016-10-12 |
2022-11-22 |
フェルダン・バイオ・インコーポレーテッド |
ポリペプチドカーゴを標的真核細胞の細胞外間隙からサイトゾルおよび／または核に送達するための合理的に設計された合成ペプチドシャトル剤、その使用、それに関連する方法およびキット
|
|
WO2018115189A1
(en)
*
|
2016-12-21 |
2018-06-28 |
Cellectis |
Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
|
|
JP2020503043A
(ja)
*
|
2016-12-30 |
2020-01-30 |
セルラリティ インコーポレイテッド |
遺伝子改変されたナチュラルキラー細胞
|
|
WO2018195339A1
(en)
*
|
2017-04-19 |
2018-10-25 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
WO2019106163A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Cellectis |
Reprogramming of genetically engineered primary immune cells
|
|
JP2023504081A
(ja)
*
|
2019-11-27 |
2023-02-01 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
神経膠芽細胞腫及び他の癌を処置するためのナチュラルキラー細胞免疫療法
|